Preferential expression of B7.2 (CD86), but not B7.1 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 21, Issue 1, 2003, Pages 71-77

  Nagafuchi, H ^a   Shimoyama, Y ^a   Kashiwakura, J ^a   Takeno, M ^a   Sakane, T ^a   Suzuki, N ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti DNA autoantibody; B7; CD40L; SLE

Indexed keywords

AUTOANTIBODY; B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; DNA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; POLYCLONAL ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CELL ACTIVITY; CELL ISOLATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LYMPHOCYTE CULTURE; MALE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ADOLESCENT; ADULT; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; CD40 LIGAND; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHYTOHEMAGGLUTININS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TETRADECANOYLPHORBOL ACETATE;

EID: 0037287976     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. SHOENFELD Y, ALARCON-SEGOVIA D, BUSKILA D et al.: Frontiers of SLE: Review of the 5th International Congress of Systemic Lupus Erythematosus, Cancun, Mexico, April 20-25, 1998. Semin Arthritis Rheum 1999; 29: 112-30.
2. MASON LJ, ISENBERG DA: Immunopathogenesis of SLE. Baillieres Clin Rheumatol 1998; 12: 385-403.
3. SIELING PA, PORCELLI SA, DUONG BT et al.: Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J Immunol 2000; 165: 5338-44.
4. LINSLEY PS, LEDBETTER JA: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212.
5. DE BOER M, KASRAN A, KWEKKEBOOM J, WALTER H, VANDENBERGHE P, CEUPPENS JL: Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells. Eur J Immunol 1993; 23: 3120-5.
6. DURIE FH, FOY TM, MASTERS SR, LAMAN JD, NOELLE RJ: The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 1994; 15: 406-11.
7. LIOSSIS SN, SFIKAKIS PP, TSOKOS GC: Immune cell signaling aberrations in human lupus. Immunol Res 1998; 18: 27-39.
8. ABE K, TAKASAKI Y, USHIYAMA C et al.: Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus. J Clin Immunol 1999; 19: 58-66.
9. FOLZENLOGEN D, HOFER MF, LEUNG DY, FREED JH, NEWELL MK: Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin Immunol Immunopathol 1997; 83: 199-204.
10. GRAMMER AC, LIPSKY PE: CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1417-29.
11. KATSIARI CG, LIOSSIS SN, SOULIOTIS VL, DIMOPOULOS AM, MANOUSSAKIS MN, SFIKAKIS PP: Aberrant expression of the co-stimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol 2002; 103: 54-62.
12. CROW MK, KIROU KA: Regulation of CD40 ligand expression in systemic Jupus erythematosus. Curr Opin Rheumatol 2001; 13: 361-9.
13. BIJL M, HORST G, LIMBURG PC, KALLENBERG CG: Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001; 60: 523-6.
14. SALOMON B, BLUESTONE JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225-52.
15. YELLIN MJ, THIENEL U: T cells in the pathogenesis of systemic lupus erythematosus: potential roles of CD154-CD40 interactions and costimulatory molecules. Curr Rheumatol Rep 2000; 2: 24-31.
16. NAKAJIMA A, AZUMA M, KODERA S, et al.: Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur J Immunol 1995; 25: 3060-9.
17. TAN EM, COHEN AS, FRIES JP et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
18. SUZUKI N, SAKANE T, ENGLEMAN EG: Anti-DNA antibody production by CD5+ and CD5- B cells of patients with systemic lupus erythematosus. J Clin Invest 1990; 85: 238-47.
19. KANEKO S, SUZUKI N, KOIZUMI H, YAMAMOTO S, SAKANE T: Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. Clin Exp Immunol 1997; 109: 185-93.
20. TAKENO M, NAGAFUCHI H, KANEKO S et al.: Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production. J Immunol 1997; 158: 3529-38.
21. BRENNER CA, TAM AW, NELSON PA et al.: Message amplification phenotyping (MAPPing): A technique to simultaneously measure multiple mRNAs from small numbers of cells. Biotechniques 1989; 7: 1096-103.
22. BOST KL, MASON MJ: Thapsigargin and cyclopiazonic acid initiate rapid and dramatic increases of IL-6 mRNA expression and IL-6 secretion in murine peritoneal macrophages. J Immunol 1995; 155: 285-96.
23. CHONG C, BOST KL, CLEMENTS JD: Differential production of interleukin-12 mRNA by murine macrophages in response to viable or killed Salmonella spp. Infect Immun 1996; 64:1154-60.
24. SHIMOYAMA Y, NAGAFUCHI H, SUZUKI N, OCHI T, SAKANE T: Synovium infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 2094-101.
25. RANHEIM EA, KIPPS TJ: Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis. Arthritis Rheum 1994; 37: 1637-46.
26. LEIFELD L, TRAUTWEIN C, DUMOULIN FL, MANNS MP, SAUERBRUCH T, SPENGLER U: Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol 1999; 154: 1711-20.
27. SPENGLER U, LEIFELD L, BRAUNSCHWEIGER I, DUMOULIN FL, LECHMANN M, SAUERBRUCH T: Anomalous expression of costimulatory molecules B7-1, B7-2 and CD28 in primary biliary cirrhosis. J Hepatol 1997; 26: 31-6.
28. MOCHIZUKI K, HAYASHI N, KATAYAMA K et al.: B7/BB-1 expression and hepatitis activity in liver tissues of patients with chronic hepatitis C. Hepatology 1997; 25: 713-8.
29. TODISCO E, GAIPA G, BIAGI E et al.: CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia. Leukemia 2002; 16: 2046-54.
30. PAPADOPOULOS NG, STANCIU LA, PAPI A, HOLGATE ST, JOHNSTON SL: Rhinovirus-induced alterations on peripheral blood mononuclear cell phenotype and costimulatory molecule expression in normal and atopic asthmatic subjects. Clin Exp Allergy 2002; 32: 537-42.
31. MACDONALD KP, NISHIOKA, Y, LIPSKY PE, THOMAS R: Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 1997; 100: 2404-14.
32. MOHAN C, ADAMS S, STANIK V, DATTA SK: Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993; 177: 1367-81.
33. YANG Y, WILSON JM: CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40. Science 1996; 273: 1862-4.
34. MOHAN C, SHI Y, LAMAN JD, DATTA SK: Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 1470-80.
35. EARLY GS, ZHAO W, BURNS CM: Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996; 157: 3159-64.
36. FINCK BK, LINSLEY PS, WOFSY D: Treatment of murine lupus with CTLA41g. Science 1994; 265: 1225-7.
37. DAVIS JC JR, TOTORITIS MC, ROSENBERG J, SKLENAR TA, WOFSY D: Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95-101.
38. HUANG W, SINHA J, NEWMAN J, et al.: The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1554-62.
39. LIANG B, GEE RJ, KASHGARIAN MJ, SHARPE AH, MAMULA MJ: B7 Costimulation in the development of lupus: autoimmunity arises either in the absence of B7.1/B7.2 or in the presence of anti-B7.1/B7.2 blocking antibodies. J Immunol 1999; 163: 2322-9.
40. YI Y, MCNERNEY M, DATTA SK: Regulatory defects in Cb1 and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2000; 165: 6627-34.
41. DAIKH DI, FINCK BK, LINSLEY PS, HOLLENBAUGH D, WOFSY D: Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997; 159: 3104-8.
42. DESAI-MEHTA A, LU L, RAMSEY-GOLDMAN R, DATTA SK: Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063-73.
43. KOSHY M, BERGER D, CROW MK: Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826-37.